Search results
Results From The WOW.Com Content Network
(Reuters) -The U.S. health regulator on Monday asked a host of drugmakers, including Gilead Sciences, Johnson & Johnson and Novartis, to add a serious warning on the label of their cancer ...
Ofatumumab (Arzerra) has received a black box warning regarding the potential for it to cause progressive multifocal leukoencephalopathy and hepatitis B reactivation. [16] [23] Likewise it is also advised that doctors watch cautiously for small bowel obstruction, neutropenia, thrombocytopenia, infusion reactions or an increased risk for ...
Imatinib, sold under the brand names Gleevec and Glivec (both marketed worldwide by Novartis) among others, is an oral targeted therapy medication used to treat cancer. [2] Imatinib is a small molecule inhibitor targeting multiple tyrosine kinases such as CSF1R , ABL , c-KIT , FLT3 , and PDGFR-β .
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022. [4][5] Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren; sold to ...
(Reuters) -BeiGene and Swiss drugmaker Novartis have terminated a 2021 deal to jointly develop the Hong Kong-listed company's cancer drug, the companies said on Tuesday, marking the second such ...
BERLIN (Reuters) -Novartis said on Thursday it has launched a tender offer to acquire MorphoSys, a German developer of cancer treatments, for an aggregate 2.7 billion euros ($2.9 billion).
Nilotinib, sold under the brand name Tasigna marketed worldwide by Novartis, is a medication used to treat chronic myelogenous leukemia (CML) which has the Philadelphia chromosome. [5] It may be used both in initial cases of chronic phase CML as well as in accelerated and chronic phase CML that has not responded to imatinib. [5] [6] It is taken ...
(Reuters) -Drugmaker Novartis AG said it will acquire MorphoSys AG, a developer of cancer treatments, for 2.7 billion euros ($2.9 billion), adding a promising rare bone-marrow cancer treatment ...